Furthermore, to determine whether circulating FGF23 might contribute to physiologic cardiac hypertrophy requires studies in animals with genetic modifications of the FGF23/FGFR4 signaling pathway in the heart. This evidence concerns the gene FGF23 and cardiac hypertrophy.